Hengrui Pharma(SH:600276) BOHAI SECURITIES·2025-12-26 11:36Investment Rating - The industry maintains a "Neutral" rating, and the specific company, 恒瑞医药 (Hengrui Medicine), is rated as "Buy" [53] Core Insights - The sixth batch of centralized procurement for high-value medical consumables has been officially launched, covering drug-coated balloon products and urological intervention consumables [7][8] - The first domestically produced anti-CTLA-4 monoclonal antibody, 达伯欣® (Dabaoxin), has received approval from the National Medical Products Administration (NMPA) for marketing [8] - A weight-loss version of 司美格鲁肽 (Semaglutide) has gained approval for cardiovascular indications in China [9] - The SW pharmaceutical industry index has shown a 1.43% increase, with most sub-sectors experiencing growth [41] - The industry’s price-to-earnings ratio (TTM) is reported at 50.75 times, with a valuation premium of 259% relative to the Shanghai and Shenzhen 300 index [47] Industry News - The National Medical Insurance Administration has released a new drug catalog, which is expected to enhance the market potential for related pharmaceutical companies [52] - The recent approval of various drugs and clinical trials indicates a robust pipeline for innovative treatments in the industry [25][27][29][30][31][32][35] Company Announcements - Several companies, including 丽珠集团 (Lizhu Group) and 艾力斯 (Eli Lilly), have received approvals for new drug applications and clinical trials, indicating ongoing innovation and development in the sector [25][26][27][29][30] - 恒瑞医药 has been included in the list of breakthrough therapy products, highlighting its significant advancements in drug development [27] Market Review - The overall market has shown positive trends, with the Shanghai Composite Index rising by 2.15% and the Shenzhen Component Index increasing by 3.66% during the week [41] - The pharmaceutical sector's performance reflects a general upward trend, with specific sub-sectors like chemical pharmaceuticals and medical services leading the gains [41] Weekly Strategy - The report suggests focusing on pharmaceutical companies that have products entering the medical insurance catalog, as this could lead to increased market volume and investment opportunities [52]